James Hambro & Partners 13F: Adds $3.7M to McKesson (MCK) Stake

James Hambro & Partners boosted its holdings in McKesson Corporation (NYSE:MCK) by 4,301 shares during the quarter, according to a Form 13F filing disclosed on the SEC website on October 19, 2026. The firm owned 138,952 shares of the medical distribution company valued at about $118.8 million after the purchase.

MCK McKesson Corporation

$1,010.43 ▲ +23.08% year to date

1M 3M YTD

Daily close · Oct 19, 2026

What Changed in James Hambro & Partners's McKesson Position

The fund increased its stake by 3.2%, growing from its previous total of 134,651 shares up to 138,952 shares. This modest addition builds on the firm's existing investment in the healthcare provider.

Other Institutional Activity in McKesson

Other large funds made substantial adjustments to their McKesson holdings during the same period. Brandes Investment Partners reduced its stake by 15,878 shares, ending with 172,487 shares valued at about $130.3 million. Franklin Resources, Inc. cut its position by 158,060 shares to finish with 2,905,114 shares worth approximately $2.94 billion. Massachusetts Financial Services Co. trimmed its holdings by 453,894 shares, leaving it with 2,446,386 shares valued at roughly $2.47 billion. Lone Pine Capital held 392,224 shares worth about $296.4 million.

McKesson Corporation Stock Up 0.6%

The stock recently traded around $1,010.43, sitting just below its 52-week high of $1,014.99 and well above its 52-week low of $723.68. The share price on the filing date was also $1,010.43.

Recent Earnings

McKesson reported $410.98 billion in trailing twelve month revenue alongside earnings of $37.31 per share. The company's next earnings report is scheduled for November 4, 2026.

Dividend

The company pays an annual dividend of $3.76 per share.

Insider Buying and Selling at McKesson Corporation

Company insiders completed several transactions prior to the filing. Chief Executive Officer Brian Scott Tyler sold 8,463 shares on July 7, 2026, at an average price of $793.56 for a total value of $6,715,898. Director Bradley E Lerman sold 301 shares on August 10, 2026, at $892.32 per share totaling $268,590. Officer Napoleon B Rutledge Jr sold 111 shares on September 8, 2026, at $891.45 per share for $98,951. Additionally, EVP, CIO and CTO Francisco Fraga sold 800.491 shares on October 15, 2026, at $995.80 per share under a planned trading rule, totaling $797,128.94.

Analysts Set New Price Targets

Analyst firms adjusted their views on the stock ahead of the filing. Barclays maintained an overweight rating on August 19, 2026, raising its price target to $1,000.00. RBC Capital initiated coverage on August 19, 2026, with a sector perform rating and an $845.00 price target, then reiterated that stance on September 14, 2026. Leerink Partners maintained an outperform rating on October 7, 2026, lifting its target to $1,070.00. UBS maintained a buy rating on October 16, 2026, boosting its target to $1,200.00. The stock currently holds a consensus buy rating from 14 analysts with a mean price target of $1,001.43.

About McKesson

McKesson Corporation operates as a healthcare services company based in Irving, Texas. It delivers medical supplies, pharmaceutical products, and technology solutions across North America through segments focused on medical distribution, oncology care, and prescription technology.

Bottom Line

Investors will look toward the upcoming earnings release on November 4, 2026, to gauge the company's financial momentum following these institutional updates.